OncBioMune Pharmaceuticals Net income (Q1, 2019)-4.4 M
OncBioMune Pharmaceuticals EBIT (Q1, 2019)-563.1 K

OncBioMune Pharmaceuticals Income Statement

OncBioMune Pharmaceuticals Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

13.0k672.8k1.4k201.0

Current Assets

17.9k709.5k41.3k14.1k215.9k

PP&E

10.7k9.6k6.6k4.3k

Total Assets

349.2k726.6k57.3k27.2k226.6k

Accounts Payable

106.0k121.6k213.6k378.2k550.3k

Short-term debt

538.9k538.9k

Current Liabilities

171.3k883.9k14.8m7.8m

Long-term debt

49.7k99.7k538.9k538.9k

Total Debt

49.7k99.7k1.1m1.1m

Total Liabilities

970.1k

Additional Paid-in Capital

2.7m1.7m2.3m8.8m9.6m

Retained Earnings

(1.1m)(3.1m)(23.7m)(17.2m)

Total Equity

(620.8k)555.4k(826.6k)(14.8m)(7.5m)

Debt to Equity Ratio

-0.1 x

Debt to Assets Ratio

39.7 x

Financial Leverage

-0.6 x1.3 x-0.1 x0 x0 x

OncBioMune Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(757.4k)(990.4k)(2.0m)(20.5m)6.5m

Depreciation and Amortization

274.01.1k3.7k2.3k

Accounts Payable

1.3k(23.1k)111.3k164.6k172.1k

Cash From Operating Activities

(372.2k)(851.8k)(1.5m)(2.3m)(1.7m)

Purchases of PP&E

(11.0k)(715.0)

Cash From Investing Activities

(152.3k)(6.3k)(20.5k)

Long-term Borrowings

(40.0k)(96.4k)(415.8k)

Cash From Financing Activities

1.4m871.2k2.3m1.7m

Interest Paid

2.5k9.2k314.5k243.9k

Quarterly